628732-15-0

Basic information

• Product Name: 1H-Indene-1-ethanol,4,5-difluoro-2,3-dihydro-(9CI)
• Synonyms: 1H-Indene-1-ethanol,4,5-difluoro-2,3-dihydro-(9CI)
• CAS NO: 628732-15-0
• Molecular Formula: C11H12F2O
• Molecular Weight: 198.2091864
• Product Categories: CYCLOPENTANE
• Mol File: 628732-15-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indene-1-ethanol,4,5-difluoro-2,3-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indene-1-ethanol,4,5-difluoro-2,3-dihydro-(9CI)(628732-15-0)
• EPA Substance Registry System: 1H-Indene-1-ethanol,4,5-difluoro-2,3-dihydro-(9CI)(628732-15-0)

Safety Data

• Hazardous Substances Data: 628732-15-0(Hazardous Substances Data)

Upstream product

• 628732-14-9 (4,5-difluoro-indan-1-yl)-acetic acid ethyl ester 
• 236746-13-7 2,3-difluorocinnamic acid 
• 628732-13-8 (4,5-difluoro-indan-1-ylidene)-acetic acid ethyl ester 
• 628732-11-6 4,5-difluoro-2,3-dihydro-1H-inden-1-one 
• 412961-26-3 3-(2,3-difluoro-phenyl)-propionic acid 
• 628732-12-7 (4,5-difluoro-1-hydroxy-indan-1-yl)-acetic acid ethyl ester 

Relevant articles and documents

4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same

The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.